Similarly, the combination therapy based on Trastuzumab emtansine and the selective anti-HER2 tyrosine kinase inhibitor (TKI) tucatinib achieved remarkable benefits in metastatic breast cancer (Nader-Marta et al., 2022) and the administration of bevacizumab, the mAb targeting the Vascular-Endothelial Growth Factor (VEGF), with Mirvetuximab soravtansine obtained similar benefits in preclinal models of ovarian cancer (Ponte et al., 2016). The gene discussed is VEGFA; the disease is ovarian carcinoma.